表紙
市場調查報告書

全球人體微生物群定序市場:各產品、技術、用途、終端用戶、各國資料(17個國家),競爭趨勢 - 分析與預測(2018∼2029年)

Global Human Microbiome Sequencing Market: Focus on Products, Technologies, Applications, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029

出版商 BIS Research Inc. 商品編碼 933141
出版日期 內容資訊 英文 222 Pages
商品交期: 最快1-2個工作天內
價格
全球人體微生物群定序市場:各產品、技術、用途、終端用戶、各國資料(17個國家),競爭趨勢 - 分析與預測(2018∼2029年) Global Human Microbiome Sequencing Market: Focus on Products, Technologies, Applications, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029
出版日期: 2020年03月31日內容資訊: 英文 222 Pages
簡介

全球人體微生物群定序市場至2029年預計將成為63億3,640萬美元的規模。該市場,由於對消費者的直銷經營模式,加入此市場的主要企業非常多,而有很大的成長。

本報告提供全球人體微生物群定序市場相關調查,市場概要和各市場區隔趨勢,各地區趨勢,及主要企業的簡介相關資訊彙整。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查方法

第4章 產業分析

  • 概要
  • 美國的法律要求事項和架構
  • 歐洲的法律上的要求事項和架構
  • 亞太地區的法律上的要求事項和架構
  • 專利分析

第5章 競爭環境

  • 協同效應
  • 產品與上市升級
  • 商務擴大與資金籌措
  • 合併、收購
  • 產品認證和其他的活動
  • 市場佔有率分析
  • 成長佔有率分析

第6章 市場趨勢

  • 概要
  • Iceberg分析
  • 影響分析
  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會

第7章 人體微生物群定序:概要

  • 簡介
  • 人體微生物群研究的里程碑
  • 人體微生物群定序的市場可用性

第8章 各產品類型市場

  • 概要
  • 套件、化驗
  • 計量儀器
  • 軟體

第9章 各技術市場

  • 概要
  • 次世代定序
  • 傳統定序技術
  • 其他定序技術

第10章 各用途市場

  • 概要
  • 疾病診斷
  • 藥物研發
  • 消費者健康
  • 體學分析
  • 其他的用途

第11章 各終端用戶市場

  • 概要
  • 研究、學術機構
  • 製藥公司,生物科技企業
  • 其他終端用戶

第12章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第13章 企業簡介

目錄
Product Code: BH186A

Global Human Microbiome Sequencing Market to Reach $6,336.4 Million by 2029

Key Questions Answered in this Report:

  • What are the long-term and short-term impacts of human microbiome sequencing on the human health continuum?
  • What are the major market drivers, challenges, and opportunities in the global human microbiome sequencing market?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global human microbiome sequencing market?
  • How is the patent landscape in the industry shaping up future technological trends?
  • How is each segment of the market expected to grow during the forecast period from 2019 to 2029?
  • Who are the leading players with significant offerings to the global human microbiome sequencing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are challenges that are yet to be met by the global human microbiome sequencing market?

Key USPs of the Report

Following are some of the key sections of the report

Industry Analysis (Section 4)

The industry analysis section encompasses analyses such as patent analysis, regulatory landscape, and awaited technological developments. The patent analysis section covers the filing trend and analyzes their growing impact on the market. This section will aid the readers in staying updated with the latest regulations as well as discuss how the market is likely to unfold during the next ten years.

Competitive Landscape (section 5)

The section comprises the following information:

Market Share Analysis

The section includes key insights on the revenue share of the players operating in the market, both for manufacturers and service providers. It will provide information on who the leading players in the market are. The section will also include growth share analysis of the key players and key applications in the study.

Key Strategies and Developments

The section provides information on the recent developments in the market, which includes the following categories - funding activities, M&A activities, partnerships, alliances & business expansions, regulatory & legal, new offerings, and procurement & sales.

Global Market Scenario (section 6)

The section encompasses the detailed description and impact analysis for the market dynamics, i.e., growth factors, challenges, and market opportunities.

In addition, the report provides a detailed analysis and growth forecast for each segment in the subsequent sections. Country-wise analysis has been provided for 17 leading countries across the globe.

Expert Quote

Market Potential

"I believe that the market size for human microbiome sequencing will be in excess of $6.00 Billion by 2029 and will grow rapidly due to the large number of initiatives that are being undertaken globally. In addition, the decreasing cost of sequencing and emergence of star-ups in the direct-to-consumer market will increasingly bolster the overall market scenario."

End-to-End Service Providers

"The industry has been largely driven by the very high number of companies entering the market through their direct-to-consumer business model. Companies such as Viome, Inc. are uniquely poised to disrupt the market with the kind of funding they have been receiving. In addition, consumer wellness is anticipated to become a centerpiece for this massively growing market, especially with a growing focus on skin microbiome."

Scope of the Global Human Microbiome Sequencing Market

The report constitutes an in-depth study of the global human microbiome sequencing market. The study also presents a detailed analysis of the market dynamics and estimation of the market size over the forecast period, 2019-2029. The scope of this report is focused on the analysis of the human microbiome sequencing market by product type, by technology, by application, by end user, and their country-wise analysis.

Key Companies in the Global Human Microbiome Sequencing Market

Some of the key players contributing to the global human microbiome sequencing market are Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., and Molzym GmbH & Co. KG.

Executive Summary

1 Product-Service Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report
  • 2.3 Global Human Microbiome Sequencing Market: Research Methodology

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Industry Analysis

  • 4.1 Overview
  • 4.2 Legal Requirements and Framework in the U.S.
  • 4.3 Legal Requirements and Framework in Europe
  • 4.4 Legal Requirements and Framework in Asia-Pacific
    • 4.4.1 China
    • 4.4.2 Japan
  • 4.5 Patent Analysis

5 Competitive Landscape

  • 5.1 Synergistic Activities
  • 5.2 Product Launches and Upgrades
  • 5.3 Business Expansion and Funding Activities
  • 5.4 Mergers and Acquisitions
  • 5.5 Product Approvals and Other Activities
  • 5.6 Market Share Analysis, 2017-2018
  • 5.7 Growth Share Analysis
    • 5.7.1 Growth Share Analysis (by Company)
    • 5.7.2 Growth Share Analysis (by Application)

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Iceberg Analysis - Global Human Microbiome Sequencing Market
  • 6.3 Impact Analysis
  • 6.4 Market Drivers
    • 6.4.1 Increasing Emphasis on Microbiome's Potential for Human Health
    • 6.4.2 Decreasing Cost of Sequencing
    • 6.4.3 Increasing Entry of Legacy Companies into Microbiome Sequencing
  • 6.5 Market Restraints
    • 6.5.1 Lack of High Complexity Testing Centers
    • 6.5.2 Insufficient Application-Based Research Hindering Market Pull
    • 6.5.3 Regulatory Challenges for Direct-to-Consumer (DTC) Companies
  • 6.6 Market Opportunities
    • 6.6.1 Massive Scope for Adoption of Human Microbiome Sequencing in Developing Nations
    • 6.6.2 Growing Integrative Industry-Academia Collaboration
    • 6.6.3 Novel Diagnostic Applications

7 Human Microbiome Sequencing: Overview

  • 7.1 Introduction
  • 7.2 Milestones in Human Microbiota Research
  • 7.3 Market Availability for Human Microbiome Sequencing

8 Global Human Microbiome Sequencing Market (by Product Type)

  • 8.1 Overview
  • 8.2 Kits and Assays
  • 8.3 Instruments
  • 8.4 Software

9 Global Human Microbiome Sequencing Market (by Technology)

  • 9.1 Overview
  • 9.2 Next-Generation Sequencing
    • 9.2.1 Sequencing by Synthesis
    • 9.2.2 Sequencing by Ligation
    • 9.2.3 Other Next-Generation Sequencing Technologies
  • 9.3 Traditional Sequencing Technologies
    • 9.3.1 Pyrosequencing
    • 9.3.2 Sanger Sequencing
  • 9.4 Other Sequencing Technologies

10 Global Human Microbiome Sequencing Market (by Application)

  • 10.1 Overview
  • 10.2 Disease Diagnosis
    • 10.2.1 Gastrointestinal Diseases
    • 10.2.2 Metabolic Diseases
    • 10.2.3 Oncology
    • 10.2.4 Infectious Diseases
    • 10.2.5 Neurological Diseases
    • 10.2.6 Other Diseases
  • 10.3 Drug Discovery
  • 10.4 Consumer Wellness
  • 10.5 Omics Analysis
    • 10.5.1 Genome Analysis
    • 10.5.2 Metabolome Analysis
    • 10.5.3 Transcriptome Analysis
    • 10.5.4 Other Omics Analysis
  • 10.6 Other Applications

11 Global Human Microbiome Sequencing (by End User)

  • 11.1 Overview
  • 11.2 Research and Academic Institutions
  • 11.3 Pharmaceutical and Biotechnology Companies
  • 11.4 Other End Users

12 Global Human Microbiome Sequencing Market (by Region)

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 France
    • 12.3.3 U.K.
    • 12.3.4 Spain
    • 12.3.5 Italy
    • 12.3.6 Russia
    • 12.3.7 Rest-of-Europe
  • 12.4 Asia-Pacific
    • 12.4.1 China
    • 12.4.2 Japan
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 South Korea
    • 12.4.6 Singapore
    • 12.4.7 Rest-of-APAC
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Argentina
    • 12.5.4 Rest-of-Latin America
  • 12.6 Rest-of-the-World

13 Company Profiles

  • 13.1 Overview
  • 13.2 Market Value Chain
  • 13.3 Baseclear B.V.
    • 13.3.1 Company Overview
    • 13.3.2 Role of Baseclear B.V. in the Global Human Microbiome Sequencing Market
    • 13.3.3 SWOT Analysis
  • 13.4 Beijing Genomics Institute (BGI) Genomics Co., Ltd
    • 13.4.1 Company Overview
    • 13.4.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global RNA Sequencing Market
    • 13.4.3 Financials
    • 13.4.4 Key Insights About Financial Health of the Company
    • 13.4.5 SWOT Analysis
  • 13.5 Charles River Laboratories International Inc.
    • 13.5.1 Company Overview
    • 13.5.2 Role of Charles River Laboratories International Inc. in the Global Human Microbiome Sequencing Market
    • 13.5.3 Financials
    • 13.5.4 SWOT Analysis
  • 13.6 Clinical Microbiomics A/S
    • 13.6.1 Company Overview
    • 13.6.2 Role of Clinical Microbiomics A/S in the Global Human Microbiome Sequencing Market
    • 13.6.3 SWOT Analysis
  • 13.7 Eurofins Scientific SE
    • 13.7.1 Company Overview
    • 13.7.2 Role of Eurofins Scientific SE in the Global Human Microbiome Sequencing Market
    • 13.7.3 Financials
    • 13.7.4 SWOT Analysis
  • 13.8 GENEWIZ, Inc.
    • 13.8.1 Company Overview
    • 13.8.2 Role of GENEWIZ, Inc. in the Global Human Microbiome Sequencing Market
    • 13.8.3 SWOT Analysis
  • 13.9 Illumina, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Role of Illumina, Inc. in the Global Human Microbiome Sequencing Market
    • 13.9.3 Financials
    • 13.9.4 Key Insights About Financial Health of the Company
    • 13.9.5 SWOT Analysis
  • 13.10 Novogene Corporation
    • 13.10.1 Company Overview
    • 13.10.2 Role of Novogene Corporation in the Global Human Microbiome Sequencing Market
    • 13.10.3 SWOT Analysis
  • 13.11 OraSure Technologies, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Role of OraSure Technologies, Inc. in the Global Human Microbiome Sequencing Market
    • 13.11.3 Financials
    • 13.11.4 Key Insights About Financial Health of the Company
    • 13.11.5 SWOT Analysis
  • 13.12 Oxford Nanopore Technologies, Inc.
    • 13.12.1 Company Overview
    • 13.12.2 Role of Oxford Nanopore Technologies, Inc. in the Global Human Microbiome Sequencing Market
    • 13.12.3 SWOT Analysis
  • 13.13 Pacific Biosciences of California, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 Role of Pacific Biosciences of California, Inc. in the Global Human Microbiome Sequencing Market
    • 13.13.3 Financials
    • 13.13.4 Key Insights About Financial Health of the Company
    • 13.13.5 SWOT Analysis
  • 13.14 QIAGEN N.V.
    • 13.14.1 Company Overview
    • 13.14.2 Role of QIAGEN N.V. plc in the Global Human Microbiome Sequencing Market
    • 13.14.3 Financials
    • 13.14.4 Key Insights About Financial Health of the Company
    • 13.14.5 SWOT Analysis
  • 13.15 Second Genome, Inc.
    • 13.15.1 Company Overview
    • 13.15.2 Role of Second Genome, Inc. in the Global Human Microbiome Sequencing Market
    • 13.15.3 SWOT Analysis
  • 13.16 Thermo Fisher Scientific Inc.
    • 13.16.1 Company Overview
    • 13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Human Microbiome Sequencing Market
    • 13.16.3 Financials
    • 13.16.4 Key Insights About Financial Health of the Company
    • 13.16.5 SWOT Analysis
  • 13.17 Viome, Inc.
    • 13.17.1 Company Overview
    • 13.17.2 Role of Viome, Inc. in the Global Human Microbiome Sequencing Market
    • 13.17.3 SWOT Analysis
  • 13.18 CosmosID
    • 13.18.1 Company Overview
    • 13.18.2 Role of CosmosID in the Global Human Microbiome Sequencing Market
  • 13.19 Leucine Rich Bio Pvt. Ltd.
    • 13.19.1 Company Overview
    • 13.19.2 Role of Leucine Rich Bio Pvt. Ltd. in the Global Human Microbiome Sequencing Market
  • 13.20 Microba
    • 13.20.1 Company Overview
    • 13.20.2 Role of Microba in the Global Human Microbiome Sequencing Market
  • 13.21 Microbiome Insights Inc.
    • 13.21.1 Company Overview
    • 13.21.2 Role of Microbiome Insights Inc. in the Global Human Microbiome Sequencing Market
  • 13.22 Molzym GmbH & Co. KG
    • 13.22.1 Company Overview
    • 13.22.2 Role of Molzym GmbH & Co. KG in the Global Human Microbiome Sequencing Market

List of Tables

  • Table 8.1: Examples of Kits and Assays in Global Human Microbiome Sequencing Market
  • Table 8.2: Examples of Instruments in Global Human Microbiome Sequencing Market
  • Table 8.3: Examples of Software in Global Human Microbiome Sequencing Market

List of Figures

  • Figure 1: Annual NIH Funding in Human Microbiome Research, FY2007-FY2016
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Human Microbiome Sequencing Market
  • Figure 3: Global Human Microbiome Sequencing Market (by Product), 2018 vs. 2029 ($Million)
  • Figure 4: Global Human Microbiome Sequencing Market (by Technology), 2018 vs. 2029 ($Million)
  • Figure 5: Global Human Microbiome Sequencing Market (by Application), 2018 vs. 2029 ($Million)
  • Figure 6: Global Human Microbiome Sequencing Market (by End User), 2018 vs. 2029 ($Million)
  • Figure 7: Global Human Microbiome Sequencing Market Snapshot
  • Figure 2.1: Global Human Microbiome Sequencing Market Segmentation
  • Figure 2.2: Global Human Microbiome Sequencing Market Methodology
  • Figure 3.1: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.2: Top-Down Approach (Segment-Wise Analysis)
  • Figure 5.1: Share of Key Developments and Strategies, January 2016-February 2020
  • Figure 5.2: Synergistic Activities Share (by Company), January 2016-February 2020
  • Figure 5.3: Product Launches Share (by Company), January 2016 - February 2020
  • Figure 5.4: Business Expansion Activities Share (by Company), January 2016 - February 2020
  • Figure 5.5: Market Share Analysis for Global Human Microbiome Sequencing Market, 2017 and 2018
  • Figure 5.6: Growth Share Analysis for Global Human Microbiome Sequencing Market (by Company), 2018
  • Figure 5.7: Growth Share Analysis for Global Human Microbiome Sequencing Market (by Application), 2018-2029
  • Figure 6.1: Iceberg Analysis - Global Human Microbiome Sequencing Market
  • Figure 6.2: Impact Analysis
  • Figure 6.3: Annual NIH Funding in the Human Microbiome Research, FY2007-FY2016
  • Figure 6.4: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 7.1: Milestones in Human Microbiota Research
  • Figure 7.2: Global Human Microbiome Sequencing Market, 2018-2029
  • Figure 8.1: Global Human Microbiome Sequencing Market (by Product Type)
  • Figure 8.2: Global Human Microbiome Sequencing Market (by Product Type), 2018 and 2029
  • Figure 8.3: Global Human Microbiome Sequencing Market (by Kits and Assays), 2018-2029
  • Figure 8.4: Global Human Microbiome Sequencing Market (by Instruments), 2018-2029
  • Figure 8.5: Global Human Microbiome Sequencing Market (by Software), 2018-2029
  • Figure 9.1: Global Human Microbiome Sequencing Market (by Technology)
  • Figure 9.2: Global Human Microbiome Sequencing Market (by Technology), 2018-2029
  • Figure 9.3: Global Human Microbiome Sequencing Market (by Next-Generation Sequencing), 2018 and 2029
  • Figure 9.4: Global Human Microbiome Sequencing Market (by Sequencing by Synthesis), 2018-2029
  • Figure 9.5: Global Human Microbiome Sequencing Market (by Sequencing by Ligation), 2018-2029
  • Figure 9.6: Global Human Microbiome Sequencing Market (by Other Next-Generation Sequencing Technologies), 2018-2029
  • Figure 9.7: Global Human Microbiome Sequencing Market (by Traditional Sequencing Technologies), 2018 and 2029
  • Figure 9.8: Global Human Microbiome Sequencing Market (by Pyrosequencing), 2018-2029
  • Figure 9.9: Global Human Microbiome Sequencing Market (by Sanger Sequencing), 2018-2029
  • Figure 9.10: Global Human Microbiome Sequencing Market (by Other Sequencing Technologies), 2018-2029
  • Figure 10.1: Global Human Microbiome Sequencing Market (by Application)
  • Figure 10.2: Global Human Microbiome Sequencing Market (by Application), 2018-2029
  • Figure 10.3: Global Human Microbiome Sequencing Market (by Disease Diagnosis), 2018 and 2029
  • Figure 10.4: Global Human Microbiome Sequencing Market (Gastrointestinal Disease), 2018-2029
  • Figure 10.5: Global Human Microbiome Sequencing Market (by Metabolic Diseases), 2018-2029
  • Figure 10.6: Global Human Microbiome Sequencing Market (by Oncology), 2018-2029
  • Figure 10.7: Global Human Microbiome Sequencing Market (Infectious Diseases), 2018-2029
  • Figure 10.8: Global Human Microbiome Sequencing Market (Neurological Diseases), 2018-2029
  • Figure 10.9: Global Human Microbiome Sequencing Market (Other Diseases), 2018-2029
  • Figure 10.10: Global Human Microbiome Sequencing Market (by Drug Discovery), 2018-2029
  • Figure 10.11: Global Human Microbiome Sequencing Market (by Drug Discovery), 2018-2029
  • Figure 10.12: Global Human Microbiome Sequencing Market (by Omics Analysis), 2018 and 2029
  • Figure 10.13: Global Human Microbiome Sequencing Market (by Genome Analysis),2018-2029
  • Figure 10.14: Global Human Microbiome Sequencing Market (by Metabolome Analysis), 2018-2029
  • Figure 10.15: Global Human Microbiome Sequencing Market (by Transcriptome Analysis), 2018-2029
  • Figure 10.16: Global Human Microbiome Sequencing Market (by Other Omics Analysis), 2018-2029
  • Figure 10.17: Global Human Microbiome Sequencing Market (by Other Applications), 2018-2029
  • Figure 11.1: Global Human Microbiome Sequencing Market (by End User)
  • Figure 11.2: Global Human Microbiome Sequencing Market (by Research and Academic Institutions), 2018-2029
  • Figure 11.3: Global Human Microbiome Sequencing Market (by Pharmaceutical and Biotechnology Companies), 2018-2029
  • Figure 11.4: Global Human Microbiome Sequencing Market (by Other End Users), 2018-2029
  • Figure 12.1: Global Human Microbiome Sequencing Market (by Region)
  • Figure 12.2: Global Human Microbiome Sequencing Market (by Region), 2018-2029
  • Figure 12.3: Global Human Microbiome Sequencing Market Share (by Region), 2018 and 2029
  • Figure 12.4: North America Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.5: North America: Market Dynamics
  • Figure 12.6: North America Human Microbiome Sequencing Market (by Country), 2018-2029
  • Figure 12.7: U.S. Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.8: Canada Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.9: Europe Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.10: Europe: Market Dynamics
  • Figure 12.11: Europe Human Microbiome Sequencing Market (by Country), 2018-2029
  • Figure 12.12: Germany Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.13: France Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.14: U.K. Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.15: Spain Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.16: Italy Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.17: Russia Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.18: Rest-of-Europe Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.19: Asia-Pacific Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.20: APAC: Market Dynamics
  • Figure 12.21: APAC Human Microbiome Sequencing Market (by Country), 2018-2029
  • Figure 12.22: China Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.23: Japan Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.24: India Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.25: Australia Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.26: South Korea Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.27: Singapore Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.28: RoAPAC Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.29: Latin America Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.30: Latin America: Market Dynamics
  • Figure 12.31: Latin America Human Microbiome Sequencing Market (by Country), 2018-2029
  • Figure 12.32: Brazil Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.33: Mexico Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.34: Argentina Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.35: Rest-of-Latin America Human Microbiome Sequencing Market, 2018-2029
  • Figure 12.36: RoW Human Microbiome Sequencing Market, 2018-2029
  • Figure 13.1: Global Human Microbiome Sequencing Market: Value Chain
  • Figure 13.2: Baseclear B.V.: Overall Service Portfolio
  • Figure 13.3: Baseclear B.V.: SWOT Analysis
  • Figure 13.4: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Service Portfolio
  • Figure 13.5: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Financials, 2017-2018
  • Figure 13.6: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Sales (by Segment), 2017-2018
  • Figure 13.7: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Sales (by Region), 2017-2018
  • Figure 13.8: Beijing Genomics Institute (BGI) Genomics Co., Ltd: R&D Expenditure, 2017-2018
  • Figure 13.9: Beijing Genomics Institute (BGI) Genomics Co., Ltd: SWOT Analysis
  • Figure 13.10: Charles River Laboratories International Inc.: Overall Service Portfolio
  • Figure 13.11: Charles River Laboratories International Inc.: Overall Financials, 2016-2018
  • Figure 13.12: Charles River Laboratories International Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.13: Charles River Laboratories International Inc.: Revenue (by Region), 2016-2018
  • Figure 13.14: Charles River Laboratories International Inc.: SWOT Analysis
  • Figure 13.15: Clinical Microbiomics A/S: Service Offerings
  • Figure 13.16: Clinical Microbiomics A/S: SWOT Analysis
  • Figure 13.17: Eurofins Scientific SE: Service Portfolio
  • Figure 13.18: Eurofins Scientific SE: Overall Financials, 2016-2018
  • Figure 13.19: Eurofins Scientific SE: Revenue (by Region), 2016-2018
  • Figure 13.20: Eurofins Scientific SE.: SWOT Analysis
  • Figure 13.21: GENEWIZ, Inc.: Overall Service Portfolio
  • Figure 13.22: GENEWIZ, Inc.: SWOT Analysis
  • Figure 13.23: Illumina, Inc.: Overall Product Portfolio
  • Figure 13.24: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 13.25: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.26: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 13.27: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 13.28: Illumina, Inc.: SWOT Analysis
  • Figure 13.29: Novogene Corporation: Overall Service Portfolio
  • Figure 13.30: Novogene Corporation: SWOT Analysis
  • Figure 13.31: OraSure Technologies, Inc.: Overall Service Portfolio
  • Figure 13.32: OraSure Technologies, Inc.: Overall Financials, 2016-2018
  • Figure 13.33: OraSure Technologies, Inc.: Sales (by Segment), 2016-2018
  • Figure 13.34: OraSure Technologies, Inc.: Sales (by Region), 2016-2018
  • Figure 13.35: OraSure Technologies, Inc.: R&D Expenditure, 2016-2018
  • Figure 13.36: OraSure Technologies, Inc.: SWOT Analysis
  • Figure 13.37: Oxford Nanopore Technologies, Inc.: Product Offerings
  • Figure 13.38: Oxford Nanopore Technologies, Inc.: SWOT Analysis
  • Figure 13.39: Pacific Biosciences of California, Inc.: Overall Product Portfolio
  • Figure 13.40: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
  • Figure 13.41: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.42: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
  • Figure 13.43: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
  • Figure 13.44: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 13.45: QIAGEN N.V.: Overall Product Portfolio
  • Figure 13.46: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 13.47: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 13.48: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 13.49: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 13.50: QIAGEN N.V.: SWOT Analysis
  • Figure 13.51: Second Genome, Inc.: Service Offerings
  • Figure 13.52: Second Genome, Inc.: SWOT Analysis
  • Figure 13.53: Thermo Fisher Scientific Inc.: Overall Product and Service Portfolio
  • Figure 13.54: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 13.55: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
  • Figure 13.56: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
  • Figure 13.57: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 13.58: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 13.59: Viome, Inc.: Product Offerings
  • Figure 13.60: Viome, Inc.: SWOT Analysis
  • Figure 13.61: CosmosID: Service Offerings
  • Figure 13.62: Leucine Rich Bio Pvt. Ltd.: Service Offerings
  • Figure 13.63: Microba: Service Offerings
  • Figure 13.64: Microbiome Insights Inc.: Service Offerings
  • Figure 13.65: Molzym GmbH & Co. KG: Product Offerings